EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
Public ClinicalTrials.gov record NCT03126435. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
Study identification
- NCT ID
- NCT03126435
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- SynCore Biotechnology Co., Ltd.
- Industry
- Enrollment
- 218 participants
Conditions and interventions
Interventions
- EndoTAG-1 Drug
- Gemcitabine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 15, 2018
- Primary completion
- Jul 29, 2021
- Completion
- Oct 7, 2021
- Last update posted
- May 5, 2023
2018 – 2021
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Compassionate Cancer Care Medical Group, Inc | Corona | California | 92879 | — |
| Emory University Hospital | Atlanta | Georgia | 30322 | — |
| John B. Amos Cancer Center / IACT Health | Columbus | Georgia | 31904 | — |
| Orchard Healthcare Research (OHR) Inc. | Skokie | Illinois | 60077 | — |
| Investigator Clinical Research Centers of Indiana | Indianapolis | Indiana | 46260-2082 | — |
| Cotton O'Neil Cancer Center (Stormont-Vail Cancer Center) | Topeka | Kansas | 66606 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| North Mississippi Hematology & Oncology Associates, Ltd. | Tupelo | Mississippi | 38801 | — |
| Southeast Nebraska Cancer Center (SNCC) - Central Clinic - Main Clinic | Lincoln | Nebraska | 68510 | — |
| Guthrie - Corning Hospital - Guthrie Cancer Center | Sayre | Pennsylvania | 18840-1625 | — |
| Charleston Cancer Center | North Charleston | South Carolina | 29406 | — |
| The Center for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
| Scott & White Vasicek Cancer Treatment Center | Temple | Texas | 76508 | — |
| Renovatioclinical | The Woodlands | Texas | 77380 | — |
| University of Virginia Hospital | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03126435, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 5, 2023 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03126435 live on ClinicalTrials.gov.